Congress trades
Emergent BioSolutions Inc. (EBS)
Free on iOS and Android.
About Emergent BioSolutions Inc.
from the company's filings and listing, as of Oct 26, 2026- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Chief executive
- Joseph C. Papa Jr.
- Employees
- 900
- Listed since
- Nov 15, 2006
- Market value
- $319.4M
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$3.43
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 2, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 5, 2026 | $0.60 | -$0.09 | $234.3M | $177.5M | EPS beatRevenue beat |
| Q1 FY2026reported Apr 30, 2026 | $0.21 | -$0.25 | $156.1M | $145.0M | EPS beatRevenue beat |
| Q4 FY2025reported Feb 26, 2026 | -$0.43 | $0.11 | $148.7M | $217.5M | EPS missRevenue miss |
| Q3 FY2025reported Oct 29, 2025 | $1.06 | -$0.12 | $231.1M | $217.5M | EPS beatRevenue beat |
| Q2 FY2025reported Aug 6, 2025 | $0.16 | -$0.26 | $140.9M | $203.7M | EPS beatRevenue miss |
| Q1 FY2025reported May 7, 2025 | $0.71 | $0.49 | $222.2M | $219.0M | EPS beatRevenue in line |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Mar 20, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Joseph PapaPresident, Chief Executive Officer and Director | $1.0M | $1.6M | $2.6M | $5.3M |
| Richard LindahlExecutive Vice President, Chief Financial Officer | $662K | $852K | $1.2M | $2.7M |
| Coleen GlessnerExecutive Vice President, Quality and Ethics and Compliance | $624K | $363K | $678K | $1.7M |
| Simon LowryChief Medical Officer and Head of Research and Development | $545K | $363K | $564K | $1.5M |
| Paul WilliamsSenior Vice President, Products Business | $495K | $363K | $534K | $1.4M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| BlackRock, Inc. | $39.5M | 4,716,599 | +8.6% | 9.14% |
| Dimensional Fund Advisors LP | $25.8M | 3,076,646 | +11.6% | 5.96% |
| State Street Corp | $24.6M | 2,929,238 | +2.8% | 5.64% |
| American Century Companies Inc | $23.2M | 2,770,448 | +14.2% | 5.37% |
| Vanguard Capital Management LLC | $18.4M | 2,198,839 | -2.6% | 4.26% |
| LSV Asset Management | $14.2M | 1,695,851 | +89.1% | 3.29% |
| Acadian Asset Management LLC | $11.3M | 1,344,323 | -2.7% | 2.61% |
| Geode Capital Management, LLC | $11.2M | 1,337,243 | +5.1% | 2.59% |
| Charles Schwab Investment Management Inc | $10.1M | 1,200,791 | -20.3% | 2.33% |
| Oak Hill Advisors LP | $9.3M | 1,113,338 | 0.0% | 2.16% |
| Millennium Management LLC | $9.0M | 1,072,185 | +101.5% | 2.08% |
| Ancora Advisors LLC | $8.9M | 1,067,867 | +160.9% | 2.07% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in EBS
13 disclosures of 13 on record · median 24d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Steve Cohen | Stock | Sale | $1,001 - $15,000 | -27.3%After the saleS&P 500 +25.1% · -52.4 pts vs S&P 500 | Dec 11, 2024 | Jan 10, 2025 | 30d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -81.2%After the saleS&P 500 +62.2% · -143.4 pts vs S&P 500 | Nov 5, 2021 | Dec 13, 2021 | 38d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -87.6%S&P 500 +69.9% · -157.5 pts vs S&P 500 | Oct 18, 2021 | Nov 15, 2021 | 28d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -89.1%After the saleS&P 500 +69.6% · -158.7 pts vs S&P 500 | Sep 15, 2021 | Oct 13, 2021 | 28d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -93.3%After the saleS&P 500 +96.1% · -189.4 pts vs S&P 500 | Feb 23, 2021 | Mar 10, 2021 | 15d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -92.1%S&P 500 +109.3% · -201.4 pts vs S&P 500 | Nov 24, 2020 | Dec 15, 2020 | 21d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -93.6%S&P 500 +134.7% · -228.3 pts vs S&P 500 | Jul 30, 2020 | Aug 19, 2020 | 20d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -91.3%S&P 500 +145.1% · -236.5 pts vs S&P 500 | Jun 19, 2020 | Jul 17, 2020 | 28d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -92.1%S&P 500 +146.5% · -238.6 pts vs S&P 500 | Jun 30, 2020 | Jul 17, 2020 | 17d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -91.2%S&P 500 +147.6% · -238.8 pts vs S&P 500 | Jun 15, 2020 | Jul 9, 2020 | 24d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -91.7%S&P 500 +152.1% · -243.8 pts vs S&P 500 | Jun 26, 2020 | Jul 9, 2020 | 13d |
| Steve Cohen | Stock | Sale | $1,001 - $15,000 | -89.1%After the saleS&P 500 +190.8% · -279.9 pts vs S&P 500 | Mar 26, 2020 | Apr 22, 2020 | 27d |
| Steve Cohen | Stock | Sale | $15,001 - $50,000 | -85.3%After the saleS&P 500 +160.0% · -245.3 pts vs S&P 500 | Aug 29, 2019 | Sep 12, 2019 | 14d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in EBS, filterable by party, chamber, type and account.
Questions
Which members of Congress have traded EBS?
Steve Cohen, Josh Gottheimer and Gilbert Ray Cisneros, Jr. disclosed EBS transactions in the filings shown here.
How quickly are EBS trades disclosed?
Congressional disclosures took a median of 24 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.